Evaluating the Effectiveness of Dermal Analgesia Provided by the Application of Lidocaine and Prilocaine Cream 5% on the Puncture Site of Axillary Blocks

October 10, 2016 updated by: Poitiers University Hospital

Prospective Study, monocentric, controlled, randomized study. Evaluating the effectiveness of dermal analgesia provided by the application of Lidocaine and Prilocaine Cream 5% on the puncture site of axillary blocks.Our study includes 70 patients. Number of subjects required for a 50% difference with the standard deviation of the control group, a significance level of 5% for a 80% power, it takes 23 people per group. Objective power of 90% obtained with 35 patients per group.

The expected benefit is the reduction of pain at the skin puncture during the realization of BAX.

Improving professional practice and quality care

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Poitiers, France, 86021
        • Service Anesthésie-Réanimation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Hospitalized for upper extremity surgery scheduled
  • Having an axillary block anesthesia.
  • Free subject, without subordination or guardianship
  • Patients undergoing a social security system or benefiting through a third party
  • Informed consent and signed by the patient after clear and honest information on the study

Exclusion Criteria:

  • Age < 18 years
  • Hypersensitivity to lidocaine, prilocaine, to one of the excipients, castor oil and its derivatives
  • Hypersensitivity to local anesthetics of the amide
  • Congenital Methemoglobinemia
  • Porphyrias
  • Glucose-6-phosphate dehydrogenase
  • Hypersensitivity to any component of Dexeryl ®
  • Disorders of atrioventricular conduction requiring permanent pacing not yet realized.
  • Epilepsy uncontrolled by treatment
  • Patients on anticoagulants
  • Skin infection from the puncture site
  • Patients with psychiatric disorders or dementia
  • Cons-indication for infusion Isofundine ®:
  • Severe congestive heart failure
  • anuria
  • oligoanuria
  • Fluid retention
  • hyperkalemia
  • hypercalcemia
  • Metabolic alkalosis
  • Patients not receiving a social security system or not qualifying through a third party
  • People receiving more protection ie minors, persons deprived of liberty by a judicial or administrative decision, guests staying in a hospital or office, adults under legal protection,
  • Pregnant or nursing women, women of childbearing age who do not have effective contraception (hormonal / mechanical: oral, injectable, transdermal, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, oophorectomy total )

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lidocaine-Prilocaine 5%
Drug: Lidocaine-Prilocaine 5%
Placebo Comparator: Dexeryl
Drug: DEXERYL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Compare the VAS groups of Lidocaine-Prilocaine 5% and Dexeryl ®
The main objective of the study is to compare the VAS (visual analogue scale) between groups of Lidocaine-Prilocaine 5% and Dexeryl ® in pain at the skin puncture for producing a block in patients undergoing axillary to an upper extremity surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
evaluation pain
- Pain during injection of mepivacaine, measured by a visual analog scale (VAS) from 0 to 100 mm,
satisfaction
- Assessment of satisfaction of anesthetists
success
The success rate of the block defined by the absence of recourse to another anesthetic technique for inadequate analgesia (the use of hypnotic anxiolytic

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Poitiers University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

July 9, 2012

First Submitted That Met QC Criteria

August 23, 2012

First Posted (Estimate)

August 28, 2012

Study Record Updates

Last Update Posted (Estimate)

October 12, 2016

Last Update Submitted That Met QC Criteria

October 10, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EMLAX 2012-001976-13

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery Scheduled

Clinical Trials on Lidocaine-Prilocaine 5%

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe